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The Lactate-to-Platelet Ratio: A Novel Predictor for Short-Term Early
Allograft Failure After Liver Transplantation
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Tatsuya Odaa, and Marwan Abouljoudb
a
Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, University of Tsukuba, Tsukuba, Ibaraki, Japan; bDepartment of
Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, Michigan, United States; and cDepartment of Clinical Trial and
Clinical Epidemiology, University of Tsukuba, Tsukuba, Ibaraki, Japan

ABSTRACT
Background. Early allograft dysfunction (EAD) is a criterion to evaluate initial graft dysfunction associated with inferior graft survival and postoperative complications after liver transplantation (LT). This study deﬁned the lactate-to-platelet ratio (LPR) as lactate level immediately
post-LT/platelet count on postoperative day 1 and evaluated its association with EAD and shortterm graft failure.
Materials and methods. This study reviewed 434 deceased-donor LTs from individuals with
conﬁrmed brain death between January 2008 and December 2014. The area under the curve
(AUC) was used to compare the predictive capacity for 3-month graft survival between EAD
and the LPR. Along with LPR, the risk factors for 3-month graft failure were analyzed by multivariate analysis.
Results. EAD was reported in 127 patients (31%). The LPR in patients with EAD was signiﬁcantly higher than that in patients without EAD (9.8 vs 5.9, P < .001). In the multivariate analysis, both the LPR (per 1.0 increase) and EAD were independent risk factors for 3-month graft
failure (hazard ratio [HR] =1.03, P = .03; and HR = 9.14, P = .001). The comparison of the
AUCs between the LPR and EAD showed no signiﬁcant difference (0.79 vs 0.78, P = .84),
whereas the combination of EAD and LPR had a better predictive capacity than EAD alone
(0.86 vs 0.78, P < .001). The LPR showed an inverse relationship for predicting 3-month graft
survival.
Conclusions. The LPR is a continuous parameter that enables prediction of initial graft function and estimation of the 3-month graft failure rate with the advantages of early availability and
simple calculations.

T

HE success and durability of liver transplantation (LT)
depends on the function of the liver graft. Initial graft dysfunction after LT presents the clinical phenotype of severe
ischemia/reperfusion (I/R) injury secondary to a variety of
recipient, donor, and perioperative factors. The parameters indicated for graft dysfunction reﬂect hepatocellular damage and
synthetic impairment [1]. Currently, early allograft dysfunction
(EAD) classiﬁcation, deﬁned by Olthoff et al [2] as a peak value
of aminotransferase >2000 IU/mL during the ﬁrst week after
LT or an international normalized ratio of ≥1.6 and/or bilirubin
≥ of 10 mg/dL at day 7, is a widely accepted criterion for initial
graft dysfunction, which results in inferior graft and patient
© 2021 Elsevier Inc. All rights reserved.
230 Park Avenue, New York, NY 10169

survival, complications, and an increase in the use of medical
resources. According to their report, the rate of graft loss was
reported to be 26.1% for patients with EAD and 3.5% for
patients without EAD; furthermore, 18.8% of patients with
EAD died, whereas only 1.8% of recipients without EAD died.
However, the EAD classiﬁcation is an “all-or-nothing” criterion, and 7 days are still needed before diagnosis.
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Platelets are the smallest constituents in blood and contain 3
types of granules: alpha granules, dense granules, and lysosomal granules. Each granule contains growth factors such as
hepatocyte growth factor, insulin-like growth factor−1, vascular endothelial growth factor, endothelial growth factor, and
serotonin. Platelets have been traditionally recognized to have
negative effects on the liver, such as under conditions of I/R
injury and hepatitis [3−5]. However, recent studies have disclosed different roles of platelets in the liver. Platelets have
been demonstrated to promote liver regeneration, ameliorate
liver ﬁbrosis, and protect hepatocytes by preventing apoptosis
[6−8]. Speciﬁcally, in the LT ﬁeld, platelets were suggested to
enhance graft regeneration after living-donor LT [9], prevent
biliary anastomotic stenosis [10], and improve graft survival
after deceased-donor LT [11,12]. It was demonstrated that platelets accumulate in the liver graft immediately after LT and
release growth factors from within, which enhances graft regeneration [13]. Lactate, a waste product of cellular metabolism, is
mainly metabolized in the liver, and post-transplant serum lactate levels are considered a surrogate marker of early graft function [14]. Abnormally elevated lactate levels may indicate graft
dysfunction. Recent studies have disclosed a relationship
between perioperative lactate levels and short-term post-LT outcomes [14,15].
In this study, we developed a novel prognostic parameter, the
lactate-to-platelet ratio (LPR), to deﬁne initial graft function
that predicts short-term graft failure after LT. This study aimed
to investigate the association of the LPR with EAD and assess
whether the LPR could predict short-term graft failure after
deceased-donor LT.
MATERIALS AND METHODS
Population
Between January 2008 and December 2014, 542 patients underwent
deceased-donor LT at the Department of Transplant and Hepatobiliary
Surgery, Henry Ford Hospital. Of these 542 patients, 48 underwent
simultaneous organ transplants, 25 received a donation from cardiac
death donors, 16 died intraoperatively, and 19 received LT under status
1A code (patient who had sudden-onset acute liver failure or had primary nonfunction of a transplanted liver within 7 days of transplantation); these patients were excluded from the analysis. A total of 434
recipients were ﬁnally enrolled in this study. The present study was
approved by the Henry Ford Health System institutional review board,
and the study was performed in accordance with the principles of the
Declaration of Helsinki.

Deﬁnition of the LPR
The LPR was deﬁned as “the lactate level immediately following LT
divided by the platelet count on postoperative day (POD) 1.” The lactate

was obtained immediately after patients were admitted to the intensive
care unit after transplantation. Lactate levels were used immediately
after LT because we previously demonstrated that a high lactate level
immediately after LT was a predictor of EAD and was strongly related
to short-term graft loss [16]. The platelet count on POD 1 was used
because the area under the curve (AUC) of the LPR for 3-month graft
loss was the highest using the value recorded on POD 5 (Table l). However, there was no remarkable difference between POD 1 and POD 5,
and regarding the platelet count, obtaining a value rapidly after LT is
clinically more important.

Outcome parameters
EAD was deﬁned following the criteria described by Olthoff et al [2].
The survival outcomes following liver transplantation (SOFT) and balanced assessment of risk (BAR) scores were calculated according to the
original articles [17,18]. Possible risk factors for 3-month graft failure
were analyzed by univariate and multivariate analyses using Cox
regression models. Warm ischemia time (WIT) and cold ischemia time
(CIT) were equally divided into 3 groups (WIT, <34 minutes, 34-42
minutes, >42 minutes; CIT, <295 minutes, 295-372 minutes, >372
minutes). The AUC, net reclassiﬁcation improvement (NRI), and integrated discrimination improvement (IDI) were used to compare the prediction abilities of EAD and the LPR for 3-month graft failure.

Statistical analysis
The results are presented as numbers and percentages. Continuous variables are expressed as medians and interquartile ranges, and groups
were compared using unpaired t tests. Univariate and multivariate analyses, coefﬁcient calculations, and operating cure analyses were performed using SPSS 21.0 (SPSS Inc., Chicago, IL, USA) and SAS
software version 9.4 (SAS Institute, Cary, NC, USA). Survival analysis
was performed using the Kaplan-Meier method, and the difference was
compared using the log-rank test. Variables that had P < .10 in the univariate analysis were included in the multivariate analysis. P < .05 was
considered statistically signiﬁcant.

RESULTS
Demographics

The median age at the time of LT was 58 years, and 278
patients were male (64%). The most common reason for LT
was hepatitis C (49%, n = 211), followed by nonalcoholic steatohepatitis or cryptogenic (29%, n = 127). The median model
for end-stage liver disease (MELD) scores, SOFT scores, and
BAR scores were 22, 3, and 7, respectively. The median length
of hospital stay was 10 days. Reoperation within 7 days
occurred in 68 patients (15%). The 3-month and 1-year survival
rates were 95% and 90%, respectively (Table 2).

Table 1. Combination of LPR: ROC Analysis for 3-Month Graft Loss
Platelet

Immediately Post-transplant

AUC
P value

Immediately post-LT

1 POD

3 POD

5 POD

0.739
.048

0.800
.013

0.711
.080

0.824
.007

AUC, area under curve; LPR, lactate/platelet ratio; LT, liver transplantation; POD, postoperative day; ROC, receiver operating characteristic.
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Table 2. Demographics (Total N = 434)
Recipient variables
Age
Sex, male
Ethnicity
White
African American
Others
Disease type
Viral hepatitis C
NASH/cryptogenic
Hepatocellular carcinoma
Cholestatic disease
Others
BMI (kg/m2)
MELD score
SOFT score
BAR score
Diabetes mellitus
Donor variables
Age
Sex, male
Ethnicity
White
African American
Others
Cause of death
CVS
Trauma
Anorexia
Others
BMI (kg/m2)
Location
Local
Regional
National
Steatosis >30%
Surgical variables, intraoperative
Warm ischemic time (min)
Cold ischemic time (min)
Estimated blood loss (ml)
Anhepatic time (min)
RBC transfusion, amount (units)
FFP transfusion, amount (units)
Platelet transfusion, amount (units)
Postoperative variables
Length of stay after transplantation, days
Biliary complications within 1 y
Rejection history within 1 y, yes
Reoperation within 30 d, yes

58 (17-72)
278 (64%)
322 (74%)
75 (17%)
37 (9%)
212 (49%)
127 (29%)
31 (7%)
33 (8%)
31 (7%)
28.0 (16.9-67.0)
22 (6-41)
3 (1-6.25)
7 (4.5-11)
112 (26%)
44 (7-84)
242 (56%)
324(75%)
89(21%)
21 (4%)
195 (45%)
117 (27%)
109 (25%)
10 (3%)
27.0 (15.1-60.6)
371 (85%)
50 (12%)
10 (3%)
7 (2%)
38 (19-92)
328 (140-699)
1800 (100-26000)
70.5 (28-179)
3 (0-48)
6 (0-57)
0 (0-35)
10 (3-142)
138 (32%)
60 (14%)
102 (24%)

BAR, balanced assessment of risk; BMI, body mass index; CVS, cardiovascular system cause; FFP, fresh frozen plasma; MELD, model of end-stage liver
disease; NASH, non-alcoholic steatohepatitis; RBC, red blood cell; SOFT, survival outcomes following liver transplantation.

EAD and the LPR

Of the 434 patients, 127 patients (31%) developed EAD.
Patients with EAD showed signiﬁcantly worse 3-month and 1year graft survival than those without EAD (86% vs 99%, P <
.001; 80% vs 94%, P < .001, Fig 1). The median LPR was 6.8
(3.8-12.8) in all the cohorts (Fig 2A), and the LPR in patients

Fig 1. Graft survival rates in patients with or without EAD.
Patients with EAD showed signiﬁcantly worse 3-month and 1year graft survival than those without EAD (3-month; 86% vs
99%, P < .001, 1-year; 80% vs 94%, P < .001). EAD, early allograft dysfunction; LPR; lactate-to-platelet ratio.

with EAD was signiﬁcantly higher than that in patients without
EAD (9.8 [3.0-16.6] vs 5.9 [1.9-10.1], P < .001, Fig 2B).

Univariate and multivariate analyses of EAD and the LPR for
predicting 3-month graft failure

The univariate analysis revealed that male sex, body mass index
>40 kg/m2, dialysis before and during transplant, CIT >372
minutes, estimated blood loss (EBL) >2000 mL, red blood cell
transfusion (per 1 unit increase), a high LPR (per 1.0 increase),
and EAD were associated with 3-month graft failure (P < .10,
Table 3). Since EBL and red blood cell transfusion were
strongly related to each other (correlation coefﬁcient r = .76),
only EBL was included in the multivariate analysis.
The multivariate analysis revealed that male sex (hazard ratio
[HR] =5.45, P = .005), dialysis before and during transplant
(HR =3.83, P = .04), a high LPR (per 1.0 increase) (HR =1.03,
P = .03), and EAD (HR =9.14, P = .001) were independent predictors of 3-month graft failure (Table 3).

AUCs, NRI values, and IDI values of the LPR, EAD
classiﬁcation, and their combination for 3-month graft failure

The AUCs of the SOFT score, BAR score, platelet count on
POD 1, lactate immediately after LT, and LPR for 3-month
graft failure were 0.62 (P = .12), 0.60 (P = .37), 0.66
(P = .05), 0.72 (P < .001), and 0.79 (P < .001), respectively.
The LPR showed an inverse relationship, with the 3-month
graft survival rate decreasing as the LPR increased (Fig 3A).
Although the NRI had better predictive ability for EAD classiﬁcation than did the LPR (P < .001, Table 4), comparison of
the AUCs between LPR and EAD classiﬁcation showed no
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signiﬁcant differences between these 2 parameters (0.79 vs
0.78, P = .84, Table 4).
The AUCs of EAD classiﬁcation alone and the combination
of EAD classiﬁcation and the LPR to predict 3-month graft
failure were 0.78 and 0.86, respectively (Table 4). A direct
comparison showed a statistically higher AUC for the combination of the EAD classiﬁcation and LPR than for the EAD
classiﬁcation alone (P < .001). Furthermore, both the NRI
(P < .001) and IDI (P = .03) showed signiﬁcantly better predictive abilities with this combination than with the EAD classiﬁcation alone (Table 4). Regardless of the presence of EAD,
the LPR showed inverse relationships for predicting 3-month
graft survival (Fig 3B).

DISCUSSION

Fig 2. EAD and the LPR. (A) Distribution of the LPR. (B) Comparison of the LPR between patients with EAD and those without
EAD. The median LPR was 6.8 (3.8-12.8) in all cohorts, and the
LPR in patients with EAD was signiﬁcantly higher than that in
patients without EAD (9.8 [3.0-16.6] vs 5.9 [1.9-10.1], P < .001).
EAD, early allograft dysfunction; LPR; lactate-to-platelet ratio.

The novelty of this study is that we developed the LPR, deﬁned
as “the lactate level immediately following LT divided by the
platelet count on POD 1,” as an early predictor for short-term
graft failure after deceased-donor LT. The LPR enables the calculation of a valid 3-month graft survival rate, which is as accurate as the EAD classiﬁcation. The LPR is a continuous
parameter that enables us to interpret initial graft function and
to calculate the 3-month graft failure rate with advantages of
early availability and simple calculations.
Because of
the increasing gap between supply and demand,
marginal livers are used more for recipients with severe disease
[19]. Initial graft dysfunction can occur in these situations and is
related to longer intensive care unit and hospital stays, higher
rates of complications, and increased mortality and graft loss.
Numerous conditions, such as donor factors (eg, steatosis, prolonged CIT, cause of death, location), recipient factors (eg, diabetes, renal failure, infection), surgical factors (eg, prolonged WIT,
blood loss, transfusions), and postoperative factors (eg, rejection,
postoperative bleeding, bile leak), can affect early graft functions
[19]. Although several scoring systems using preoperative
parameters, such as the SOFT score, BAR score, D-MELD score
and liver donor risk index, were developed to predict postoperative graft survival [17,20,21], they are mostly used for decision
making regarding donor and recipient matching prior to transplant. In fact, the SOFT and BAR scores demonstrated low accuracies in our cohort. To conduct early medical intervention and
decrease postoperative mortality and morbidity rates without
wasting medical resources, an early and accurate parameter to
judge initial graft dysfunction after LT is important. Although no
universal deﬁnition for initial graft dysfunction exists, the EAD
classiﬁcation described by Oltoff et al [2] is currently one of the
most widely accepted criteria used in the clinical ﬁeld. Validity
of the EAD classiﬁcation has been established in previous studies, including our data [22,23]. However, there are still problems
with this classiﬁcation in that it takes 7 days before diagnosis and
is an “all-or-nothing” binary criterion. Clinicians intuitively
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Table 3. Univariate and Multivariate Analysis of Risk Factors for 3-Month Graft Loss
Univariate Analysis
HR

Recipient variables
Age
Male, yes
Ethnicity, white
Disease type, hepatitis C
BMI 20-29
<20
30-40
40<
MELD score
Diabetes, pretransplant
Dialysis before and during transplant
Donor variables
Donor age
Donor ethnicity, white
Donor cause of death, CVA
Donor local, yes
Steatosis >30%, yes
Surgical variables
Warm ischemic time <34 min,
34-42 min
42 min <
Cold ischemic time <295 min,
295-372 min
372 min <
Anhepatic time >75 min, yes
Estimated blood loss >2000 mL
RBC transfusion, per 1 unit
Platelet transfusion, per 1 unit
Postoperative variables
LPR (per 1 increase)
EAD, yes
Acute cellular rejection, yes
Biliary complications, yes

Multivariate Analysis

CI

P

HR

CI

P

1.00
3.17
1.20
0.87
1.99
2.10
3.49
1.95
1.12
2.86

0.95-1.04
1.33-7.56
0.44-3.24
0.38-2.02
0.25-15.89
0.83-5.32
0.93-13.14
0.79-4.78
0.40-3.19
0.93-8.76

0.78
0.01
0.73
0.75
Reference
0.52
0.12
0.07
0.15
0.83
0.07

5.45
4.30
3.83

1.65-18.01
0.78-23.67
1.04-14.17

0.005
Reference
0.09
0.04

1.01
1.49
1.45
0.71
3.55

0.98-1.04
0.50-4.39
0.63-3.37
0.24-2.10
0.47-26.63

0.57
0.47
0.39
0.54
0.22

-

-

-

1.75
2.66
1.64
4.92
2.11
2.96
1.07
1.02

0.52-5.99
0.83-8.48
0.39-6.84
1.42-17.13
0.86-5.15
1.07-8.24
1.02-1.12
0.94-1.10

Reference
0.37
0.10
Reference
0.50
0.01
0.10
0.04
0.008
0.65

2.91
1.91
-

0.68-12.51
0.56-6.52
-

0.15
0.30
-

1.04
11.67
2.07
1.62

1.03-1.06
3.95-34.51
0.28-15.36
0.38-6.95

<0.001
<0.001
0.48
0.51

1.03
9.14
-

1.00-1.05
2.42-34.47
-

0.03
0.001
-

BMI, body mass index; CI, conﬁdence interval; CVA, cardiovascular system cause; EAD, early allograft dysfunction; HR, hazard ratio; LPR, lactate/platelet ratio;
MELD, model of end-stage liver disease; RBC, red blood cell.

understand that there is continuity between immediate graft function and primary nonfunction, and a score grading the extent of
graft function after LT would allow clinicians to objectively
assess graft dysfunction.
As a continuous parameter to understand initial graft function, the model of early allograft function was recently developed to understand the actual allograft function; this model
comprises bilirubin, international normalized ratio, and alanine
aminotransferase within 3 days post-transplant [24]. Model of
early allograft function outperformed EAD as a predictor of
transplant survival, either when used as a stand-alone parameter
or when corrected for additional independent predictors of
transplant survival [25]. However, this parameter also has some
issues: the formula is not simple, and it still requires 3 days
before a calculation can be completed. Another continuous
parameter, the liver Graft Assessment Following Transplantation (L-GrAFT) risk score, enables risk estimation of 3-month
graft failure post-LT [26]. The L-GrAFT model had an excellent
C-statistic of 0.85, with a signiﬁcantly superior discrimination

for 3-month graft survival compared with that of the EAD classiﬁcation. However, L-GrAFT needs 10 days before it can be
calculated and is constituted by 7 factors, resulting in a complex
formula.
We focused on the combination of lactate and platelets since
the postoperative platelet counts and lactate level immediately
following LT were related to post-transplant graft failure
[11,12,14,15,27]. Postoperative lactate levels are dependent on
I/R injury caused by, for example, prolonged ischemia times or
anhepatic phase time, severe steatosis, and recipient infectious
status under which lactate acidosis appears as early graft dysfunction [28]. Furthermore, recent studies have disclosed the
relationship between perioperative lactate levels and short-term
post-LT outcomes [16]. High lactate levels immediately posttransplant were related to major postoperative complications,
longer length of intensive care unit stay, and higher rates of
graft failure and mortality [14]. In addition, perioperative
thrombocytopenia is related to poor graft regeneration,
increases postoperative morbidity, and deteriorates graft and
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Table 4. AUC, NRI, and IDI of LPR, EAD, and Their Combination
for 3-Month Graft Survival
LPR vs EAD

Cox & Snell R2
Nagelkerke R2
AUC
IDI (95% CI)
NRI (95% CI)

LPR

EAD

0.039
0.118
0.789

0.062
0.187
0.777

Comparison
(LPR vs EAD)

P

0.012 (−0.104 to 0.128)
.835
−0.015 (−0.063 to 0.033)
.545
−0.859 (−1.257 to −0.4606) <.001

LPR+EAD vs EAD
LPR+EAD EAD
2

Cox & Snell R
Nagelkerke R2
AUC
IDI (95% CI)
NRI (95% CI)

0.083
0.250
0.858

0.062
0.187
0.777

Comparison
(LPR+EAD vs EAD)

0.082 (0.039-0.124)
0.056 (0.005-0.106)
0.797 (0.387-1.207)

P

<.001
.032
<.001

AUC, area under the curve; CI, conﬁdence interval; EAD, early allograft dysfunction; HR, hazard ratio; IDI, integrated discrimination improvement; LPR, lactate/platelet ratio; NRI, net reclassiﬁcation improvement.

Fig 3. LPR and 3-month graft survival. (A) The LPR alone. The
LPR showed an inverse relationship, and the 3-month graft survival rate decreased as the LPR increased. (B) Combination of
the LPR and EAD. Regardless of the inclusion of EAD, the LPR
showed inverse relationships for predicting 3-month graft survival.
EAD, early allograft dysfunction; LPR; lactate-to-platelet ratio.

patient survival in both the short term and long term after LT
[11,12,27]. In an animal model, we demonstrated that platelets
accumulated in the liver graft immediately after LT, and the
interaction of platelets with Kupffer cells at the liver graft
induced the release of cytokines such as interleuken-6 and
tumor necrosis factor−a from Kupffer cells and the secretion of
growth factors such as insulin-like growth factor−1 and hepatocyte growth factor from platelets, both of which promoted hepatocyte proliferation at the liver graft without aggravating I/R
injury [13]. Furthermore, insulin-like growth factor-1 and endothelial growth factor, which are found at high levels in platelets,
were reported to protect the liver against I/R injury [29]. These
studies explain how platelets can work as carriers of growth factors and result in platelet-induced hepatocyte proliferation and
graft protection after LT.

In our study, the higher LPR was a risk factor for predicting
3-months graft failure, which was independent from the amount
of intraoperative hemorrhage by the multivariate analysis. This
result demonstrated that LPR represents early graft function,
not merely a result inﬂuenced by hemorrhage. The LPR showed
a better predictive ability than either platelet count on POD 1 or
lactate immediately post-LT alone and was as accurate as the
EAD classiﬁcation. When combined with the EAD classiﬁcation, the LPR demonstrated better predictive ability for 3-month
graft survival than the EAD classiﬁcation alone, with a high
AUC of over 0.85. These results suggest the practical usefulness of the LPR in the real clinical environment.
We emphasize the strengths and advantages of the LPR from
the following 3 points. First, lactate level and platelet count are
promptly available with minimal invasiveness to the patient,
and the LPR can be calculated with a simple formula. Second,
the EAD classiﬁcation, a widely accepted criterion to predict
poor graft function, has the limitation of requiring 7 days before
diagnosis, which could miss the optimal timing for medical
intervention. By contrast, the LPR is available 1 day after surgery, which can help clinicians implement early medical interventions to potentially prolong graft survival, such as N-acetyl
cysteine, vitamin E, and prostaglandin E1, as needed [19].
Third, although the EAD classiﬁcation is simply a binary classiﬁcation that reﬂects early graft function, the LPR is a continuous parameter that enables us to estimate graft function and
calculate the probability for 3-month graft survival post-LT.
We acknowledge several limitations of our study. First, the
data are retrospective in nature with a small number of patients.
In addition, we could not validate the utility of the LPR. Validation with prognosis prediction models in other cohorts is necessary. Second, the median MELD score for transplantation was
lower than the median national score. Thus, the preoperative

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on February 15, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

LACTATE-TO-PLATELET RATIO AND ALLOGRAFT FAILURE

general condition in our patients was better, and we might have
obtained different results if we included patients with higher
MELD scores. Third, we could not ﬁnd any relationship of the
LPR with mid- or long-term graft survival. We speculate that
other factors, including rejection, infection, and de novo malignancy, could affect mid- or long-term graft survival more so
than lactate levels and the platelet count immediately after posttransplantation. Despite these limitations, we emphasize the
importance of the LPR in that it is one of the earliest predictors
to estimate the short-term graft survival rate and understand
allograft function, and it is as useful as the EAD classiﬁcation.

CONCLUSIONS

The LPR is a continuous parameter that enables the prediction
of 3-month graft failure with the advantages of early availability
and simple calculations.
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